Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in Late Antibody-Mediated Renal Transplant Rejection
2024-511764-86-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2 trial of felzartamab in Antibody-mediated rejection of kidney allograft (ABMR), sponsored by Medical University of Vienna. Planned start Dec 2024; status: authorised.
02
Drugs
felzartamab
03
Conditions
Antibody-mediated rejection of kidney allograft (ABMR)
Beyond the preview
Go deeper on 2024-511764-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511764-86-00.